As profG has made the post here is the data
First up we have Asplund Högelin, Klara and Ruffin, Nicolas and Pin, Elisa and Månberg, Anna and Hober, Sophia and Gafvelin, Guro and Grönlund, Hans and Nilsson, Peter and Khademi, Mohsen and Olsson, Tomas and Piehl, Fredrik and Al Nimer, Faiez, Development of Humoral and Cellular Immunological Memory Against SARS-CoV-2 Despite B-Cell Depleting Treatment in Multiple Sclerosis. SSRN: http://dx.doi.org/10.2139/ssrn.3796531
Korgsgaard et al AAN P15.01 Preliminary results of ongoing prospective study of antibody and T cell responses to SARS-Cov-2 in patients with MD on ocrelizumab or other disease modifying therapies
Assays upto 9 months after infection
Antibody Assay Ocrelizumab Non-Ocrelizumab
Elecsys (Spike) 58% (n=19 97% (n=36) p=0.0004
Bead Assay multiple 89% (n=18) 97% (n=34) P=0.27
Neutralizing Antibody (Spike) 62% (n=16) 83% (n=19) P=0.74
T CELL ASSAY
ELISPOT (gamma interferon) 80% (n=10) 82% (n=17)
TruCulture interferon & IL-12 39% (n=17) 39% (n=26)
So there is a T cell response in people treated with ocreliziumab. This is good news but this group will not be typical of the general population, who show no or mild symptoms as it is clear that for many people infected with COVID-19 the antibodies don’t hang around for ever.
Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust or Queen Mary Univeristy of London.